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Discussion
Dr Marc Ruel (Ottawa, Ontario, Canada). I enjoyed your presen-
tation. I regularly perform MVST as well. I think it is a great oper-
ation. I wanted to ask you a couple of technical questions about this
operation.
First, I see that most of your patients underwent 2-vessel revas-
cularization. As you know, it is possible to do complete triple-vessel
revascularization. With regard to that, how often do you bypass the
right artery or its branches, and if you do a 3-vessel revasculariza-
tion, what is your conduit selection strategy?
Dr Kon. Thank you. I am going to defer this question to my
primary investigator.
Dr Poston. I am Robert Poston, senior author of the study and
the one who did these procedures. The question of whether we in-
completely revascularized our patients who underwent a minimally
invasive approach is important. We do not want to emphasize the
use of minithoracotomy and having the patient leave the hospital
sooner more than performing an effective operation. As shown in
the slide, we actually had 2.5 diseased vessels in the MVST group,
the hybrid group had 2.7, and our standard OPCAB total is 2.8. I
agree with you that these patients had less total disease than you
might see with a typical CABG referral that requires 3- or 4-vessel
grafting. However, the minimally invasive and sternotomy groups
were fairly comparable in terms of their disease. In addition, the ratio
of the number of diseased to the number of revascularized vessels
was also similar between groups, with only a slight reduction in
the MVST group at 0.88, which was not likely to be clinically
significant.
The most compelling case about choosing the minimally inva-
sive surgery approach is the use of arterial grafts and avoiding the
limitations of the vein grafts that are used in 95% of sternotomy
cases. We know that vein grafts are going to fail at a higher rate
both at the early time point and at rates of up to 30% at 1 year, as
evidenced by the recently published PREVENT IV trial.
Dr Valavanur Subramanian (New York, NY). We presented our
multivessel/small vessel thoracotomy for multiple coronary artery
bypass, paving the way for outpatient surgery. Our length of stay
was actually very good—less than 3 days in the majority of the
patients—and about 50% went home 14 hours after the operation.
Therefore my question is this: If you are able to perform multiple
arterial grafting through theMVST approach, why the hybrid proce-
dure, except for the right coronary artery?
Dr Kon. A lot of that has to do with the right coronary artery.
You are limited to the lateral anterior surface of the heart, whereas
the hybrid procedure allows you to really revascularize right-sided
lesions.
Dr Poston. I would echo that. It is just technically much more
straightforward to put a stent in a vessel going to the posterior heart
than to try to graft that. Therefore that was always our first choice,
particularly with the use of a coated stent that is going to perform
quite well in the long term compared with a vein graft. A case can
be made that the stent might exceed the results of even the radial
artery graft because you do not have to deal with conduit spasm,
an issue that has not completely been resolved with the radial artery.
There might even be an increased propensity to spasm when the ra-
dial artery is used as a Y graft, which is the rule for minimally inva-
sive cases. Therefore if we had a good candidate with a stentable
right or circumflex artery, but particularly for the right coronary
artery, as you suggested, then the hybrid procedure was the first
choice for our minimally invasive program.
DrMichael A. Acker (Philadelphia, Pa). Rob, with the new in-
formation about the drug-eluting stents, do you still feel that way?
When you put a drug-eluting stent in now, it is really an issue for
life. You have all seen these acute thromboses, and it is now being
recognized, even by the cardiology community, where the pendu-
lum is swinging, because now they want to put in the bare-metal
stents. They are nervous about the drug-eluting stents.
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Dr Poston. It depends on the quality of the target. If you are put-
ting coated stents into small coronary arteries, then that thrombosis
issue is going to be real, but if you put it into a large proximal vessel
of 3.0 mm in diameter, then it would seem that the risk of thrombosis
is going to be pretty low. According to the US Food and Drug Ad-
ministration’s preliminary analysis, the thrombosis issue is largely
related to pushing the envelope with off-label use of stents and prob-
ably not so much with the on-label use in the large coronary targets.
Dr Ralph J. Damiano (St Louis, Mo). Congratulations on your
very nice presentation. You just touched briefly on the economics of
this approach. First, I would tell you that length of stay in a non-
blinded study is extremely subjective, and I would not put much em-
phasis on those data. Saving one day in the hospital really saves you
little. Most of the cost of coronary surgery is incurred in the operat-
ing room and in the first 24 hours.
I would wonder whether you have done an economic analysis be-
cause your approach, I think, is expensive and is another reason
probably not to adopt this as opposed to just doing MVST or an OP-
CAB. Have you looked at the cost of this, including the cost of your
coated stent, and then have you looked at the cost of having to stay
on clopidogrel for a full year, which I am sure you tell your patients
to do. Basically, in most hospitals you have eliminated any possibil-
ity for any elective surgery for the next year. Therefore after a year of
including the clopidogrel cost in your hybrid group compared with
your other groups, could you describe the difference in the health
care economics of these approaches?
DrKon. Thank you very much for that question. In fact, we did
do a cost analysis because we were worried that the additional cost
of these stents would be significant. However, primarily because
the patients stayed in the hospital a shorter period of time and
ICU time and blood transfusions were reduced, we did not see
a significant increase in costs between the hybrid procedure and
OPCAB groups.
As far as clopidogrel use over 1 year, I cannot give you numbers,
but definitely in the short term total cost of the procedure and postop-
erative hospital carewas equivalent betweengroups,with only aminor
increase, which was not statistically significant, in the hybrid group.
DrMichael Mack (Dallas, Tex). Dr Kon, let me ask you 2 ques-
tions. I assume that these patients were not randomized, and if not,
why not?
Dr Kon. Traditionally, patients with 2- or 3-vessel disease in our
institution underwent a standard OPCAB sternotomy. We recently
began a minimally invasive program in which we wanted to effec-
tively do a pilot study just to see how efficacious these procedures
were, and after these findings, we certainly hope to attempt a larger
randomized trial to confirm these results.
DrMack. Threeofyour4 endpoints arevery caregiver driven: time
to extubation, ICU stay, and length of hospital stay. Were these all pro-
tocol-driven management issues because there is a wide variability in
anesthesiologists and preference for extubation and things like that?
Dr Kon. It is true that specifically hospital stay and perhaps even
ICU stay are very subjective as far as the caregiver’s decisions of
when to allow a patient to leave or to advise a patient to leave, but
that is why we specifically followed up with more objective analyses
that were not biased by the perception of the caregiver, such as inci-
sional pain time and time to return to work and overall satisfaction.
The actual decision to leave the ICU or hospital was based on
physician preference.
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